Functional characterization of AT-1001, an α3β4 nicotinic acetylcholine receptor ligand, at human α3β4 and α4β2 nAChR

Nicotine and Tobacco Research

Volumn 17, Issue 3, 2015, Pages 361-367

  Zaveri, Nurulain T ^a   Bertrand, Sonia ^b   Yasuda, Dennis ^a   Bertrand, Daniel ^b  

^a Astraea Therapeutics Inc   (Spain)

^b Rue de Compois   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; LARAZOTIDE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA3BETA4; NICOTINIC RECEPTOR ALPHA4BETA2; RECOMBINANT RECEPTOR; UNCLASSIFIED DRUG; ALPHA3BETA4ALPHA5 RECEPTOR, HUMAN; AT-1001; LIGAND; OLIGOPEPTIDE;

ACETYLCHOLINE RELEASE; ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; DRUG ACTIVITY; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VOLTAGE CLAMP TECHNIQUE; XENOPUS LAEVIS; ANIMAL; DOSE RESPONSE; FEMALE; HUMAN; METABOLISM; PARTIAL AGONISM;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG PARTIAL AGONISM; FEMALE; HUMANS; LIGANDS; OLIGOPEPTIDES; RECEPTORS, NICOTINIC; XENOPUS LAEVIS;

EID: 84942521167     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntu170     Document Type: Article

References (28)

1. Picciotto MR, Zoli M, Rimondini R, et al. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature. 1998;391:173-177.
2. Tapper AR, McKinney SL, Nashmi R, et al. Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science. 2004;306:1029-1032.
3. Corrigall WA, Franklin KB, Coen KM, Clarke PB. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology. 1992;107:285-289.
4. Maskos U, Molles BE, Pons S, et al. Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature. 2005;436:103-107.
5. McCallum SE, Parameswaran N, Bordia T, Fan H, McIntosh JM, Quik M. Differential regulation of mesolimbic alpha 3/alpha 6 beta 2 and alpha 4 beta 2 nicotinic acetylcholine receptor sites and function after long-term oral nicotine to monkeys. J Pharmacol Exp Ther. 2006;318:381-388.
6. Graupner M, Maex R, Gutkin B. Endogenous cholinergic inputs and local circuit mechanisms govern the phasic mesolimbic dopamine response to nicotine. PLoS Comput Biol. 2013;9:e1003183.
7. Weiss RB, Baker TB, Cannon DS, et al. A candidate gene approach identifies the CHRNA5-A3-B4 region as a risk factor for age-dependent nicotine addiction. PLoS Genet. 2008;4:e1000125.
8. Berrettini W, Yuan X, Tozzi F, et al. Alpha-5/alpha-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol Psychiatry. 2008;13:368-373.
9. Saccone NL, Wang JC, Breslau N, et al. The CHRNA5-CHRNA3-CHRNB4 nicotinic receptor subunit gene cluster affects risk for nicotine dependence in African-Americans and in European-Americans. Cancer Res. 2009;69:6848-6856.
10. Caporaso N, Gu F, Chatterjee N, et al. Genome-wide and candidate gene association study of cigarette smoking behaviors. PLoS One. 2009;4:e4653.
11. Schlaepfer IR, Hoft NR, Collins AC, et al. The CHRNA5/A3/B4 gene cluster variability as an important determinant of early alcohol and tobacco initiation in young adults. Biol Psychiatry. 2008;63:1039-1046.
12. Salas R, Pieri F, De Biasi M. Decreased signs of nicotine withdrawal in mice null for the beta4 nicotinic acetylcholine receptor subunit. J Neurosci. 2004;24:10035-10039.
13. Stoker AK, Olivier B, Markou A. Role of α7-and ß4-containing nicotinic acetylcholine receptors in the affective and somatic aspects of nicotine withdrawal: studies in knockout mice. Behav Genet. 2012;42:423-436.
14. Grady SR, Moretti M, Zoli M, et al. Rodent habenulo-interpeduncular pathway expresses a large variety of uncommon nAChR subtypes, but only the alpha3beta4* and alpha3beta3beta4* subtypes mediate acetylcholine release. J Neurosci. 2009;29:2272-2282.
15. Frahm S, Slimak MA, Ferrarese L, et al. Aversion to nicotine is regulated by the balanced activity of ß4 and α5 nicotinic receptor subunits in the medial habenula. Neuron. 2011;70:522-535.
16. Fowler CD, Lu Q, Johnson PM, Marks MJ, Kenny PJ. Habenular α5 nicotinic receptor subunit signalling controls nicotine intake. Nature. 2011;471:597-601.
17. Görlich A, Antolin-Fontes B, Ables JL, et al. Reexposure to nicotine during withdrawal increases the pacemaking activity of cholinergic habenular neurons. Proc Natl Acad Sci USA. 2013;110:17077-17082.
18. Gallego X, Molas S, Amador-Arjona A, et al. Overexpression of the CHRNA5/A3/B4 genomic cluster in mice increases the sensitivity to nicotine and modifies its reinforcing effects. Amino Acids. 2012;43:897-909.
19. Toll L, Zaveri NT, Polgar WE, et al. AT-1001: a high affinity and selective α3ß4 nicotinic acetylcholine receptor antagonist blocks nicotine selfadministration in rats. Neuropsychopharmacology. 2012;37:1367-1376.
20. 123I]AT-1012, a new high affinity radioligand for the α3ß4 nicotinic acetylcholine receptors. Neuropharmacology. 2014;77:193-199.
21. Hogg RC, Bandelier F, Benoit A, Dosch R, Bertrand D. An automated system for intracellular and intranuclear injection. J Neurosci Methods. 2008;169:65-75.
22. Cachelin AB, Rust G. Unusual pharmacology of ( + )-tubocurarine with rat neuronal nicotinic acetylcholine receptors containing beta 4 subunits. Mol Pharmacol. 1994;46:1168-1174.
23. Smulders CJ, Zwart R, Bermudez I, van Kleef RG, Groot-Kormelink PJ, Vijverberg HP. Cholinergic drugs potentiate human nicotinic alpha4beta2 acetylcholine receptors by a competitive mechanism. Eur J Pharmacol. 2005;509:97-108.
24. Zaveri N, Jiang F, Olsen C, Polgar W, Toll L. Novel α3ß4 nicotinic acetylcholine receptor-selective ligands. Discovery, structure-activity studies, and pharmacological evaluation. J Med Chem. 2010;53:8187-8191.
25. Buisson B, Vallejo YF, Green WN, Bertrand D. The unusual nature of epibatidine responses at the alpha4beta2 nicotinic acetylcholine receptor. Neuropharmacology. 2000;39:2561-2569.
26. Zwart R, van Kleef RG, Gotti C, Smulders CJ, Vijverberg HP. Competitive potentiation of acetylcholine effects on neuronal nicotinic receptors by acetylcholinesterase-inhibiting drugs. J Neurochem. 2000;75:2492-2500.
27. Rollema H, Shrikhande A, Ward KM, et al. Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence. Br J Pharmacol. 2010;160:334-345.
28. Rollema H, Russ C, Lee TC, Hurst RS, Bertrand D. Functional interactions of varenicline and nicotine with nAChR subtypes implicated in cardiovascular control. Nicotine Tob Res. 2014;16:733-742.